XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements

4. Fair Value Measurements

The following tables summarize the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

 

 

March 31, 2022

 

 

 

Valuation
Hierarchy

 

Amortized
Costs

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

32,747

 

 

$

 

 

$

 

 

$

32,747

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

Level 1

 

 

68,129

 

 

 

2

 

 

 

(275

)

 

 

67,856

 

Corporate debt

 

Level 2

 

 

109,752

 

 

 

2

 

 

 

(378

)

 

 

109,376

 

Commercial paper

 

Level 2

 

 

10,689

 

 

 

 

 

 

 

 

 

10,689

 

Total cash equivalents and
   short-term investments

 

 

 

$

221,317

 

 

$

4

 

 

$

(653

)

 

$

220,668

 

 

 

 

 

 

December 31, 2021

 

 

 

Valuation
Hierarchy

 

Amortized
Costs

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

60,844

 

 

$

 

 

$

 

 

$

60,844

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

Level 1

 

 

18,064

 

 

 

 

 

 

(60

)

 

 

18,004

 

Corporate debt

 

Level 2

 

 

124,178

 

 

 

2

 

 

 

(125

)

 

 

124,055

 

Commercial paper

 

Level 2

 

 

15,081

 

 

 

 

 

 

 

 

 

15,081

 

Total cash equivalents and
   short-term investments

 

 

 

$

218,167

 

 

$

2

 

 

$

(185

)

 

$

217,984

 

 

As of March 31, 2022, the remaining contractual maturities for available-for-sale securities were between one month to twelve months.

Impairment assessments are made at the individual security level at each reporting period. When the fair value of an available-for-sale security is less than its cost at the balance sheet date, a determination is made as to whether the impairment is other-than-temporary and, if it is other-than-temporary, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. There were no unrealized losses for securities in an unrealized loss position for more than 12 months as of March 31, 2022. During the three months ended March 31, 2022 and 2021, the Company did not recognize other-than-temporary impairment losses related to its investment securities.